References
  1. Zicari AM, Capata G, Nebbioso M et al. Vernal Keratoconjunctivitis: an update focused on clinical grading system. Ital J Pediatr. 2019;45(1):64.
  2. Nebbioso M, Iannaccone A, Duse M. et al., Vascular Endothelial Growth Factor (VEGF) Serological and Lacrimal Signaling in Patients Affected by Vernal Keratoconjunctivitis (VKC). J Ophthalmol. 2018;3850172.
  3. Nebbioso M, Zicari AM, Celani C et al. Pathogenesis of vernal keratoconjunctivitis and associated factors. Semin Ophthalmol. 2015;30:340-344.
  4. Zicari AM, Mora B, Pizzuti A et al. Immunogenetic investigation in vernal keratoconjunctivitis. Pediatr Allergy Immunol. 2014;25:508-510.
  5. Zicari AM, Nebbioso M, Lollobrigida V at al. Vernal keratoconjunctivitis: atopy and autoimmunity. Eur Rev Med Pharmacol Sci. 2013;17:1419-1423.
  6. Inada N, Shoji J, Shiraki Y. et al. Histamine H1 and H4 receptor expression on the ocular surface of patients with chronic allergic conjunctival diseases. Allergol Int. 2017;66:586-593.
  7. Zicari AM, Zicari A, Nebbioso M et al. High-mobility group box-1 (HMGB-1) and serum soluble receptor for advanced glycation end products (sRAGE) in children affected by vernal keratoconjunctivitis, Pediatr Allergy Immunol. 2014;25:57-63.
  8. Leonardi A, Di Stefano A, Motterle L, et al. Transforming growth factor-b/Smad - signalling pathway and conjunctival remodelling in vernal keratoconjunctivitis. Clin Exp Allergy 2011:41:52–60.
  9. Leonardi A, Fregona I, Plebani M et al. Th1- and Th2-type cytokines in chronic ocular allergy. Graefes Arch Clin Exp Ophthalmol 2006;244:1240-1245.
  10. Leonardi A, Borghesan F, Faggian D, et al. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol 2000:129:151–158.
  11. Pucci N, Caputo R, Mori F, et al. Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis. Int J Immunopathol Pharmacol 2010;23:865-871.
  12. Lambiase A, Leonardi A, Sacchetti M et al., Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study. J Allergy Clin Immunol 2011; 128: 896-897.
  13. Vichyanond P, Pacharn P, Pleyer U, et al. Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes. Pediatr Allergy Immunol. 2014;25:314-322.
  14. Dadaci Z, Oncel M, Oncel Acir N. et al. Oxidative stress parameters and serum magnesium levels in patients with seasonal allergic conjunctivitis. Cutan Ocul Toxicol. 2016;35:270-274.
  15. Bacsi A, Dharajiya N, Choudhury BK. et al. Effect of pollen-mediated oxidative stress on immediate hypersensitivity reactions and late-phase inflammation in allergic conjunctivitis. J Allergy Clin Immunol. 2005;116:836-843.
  16. Smith RE, Ozben T, Saso L. Modulation of Oxidative Stress: Pharmaceutical and Pharmacological Aspects 2018. Oxid Med Cell Longev. 2019;2019:6380473.
  17. Spadavecchia L, Fanelli P, Tesse R et al. Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol. 2006;17:527-532.
  18. Bousquet J, Heinzerling L, Bachert C, et al. Practical guide to skin 
prick tests in allergy to aeroallergens. Allergy. 2012;67:18‐24.
  19. Castelli S, Arasi S, Pawankar R, et al. Collection of nasal secretions and tears and their use in allergology. Curr Opin Allergy Clin Immunol. 2018;18:1-9.
  20. Liguori I, Russo G, Curcio F, et al. Oxidative stress, aging, and diseases. Clin Interv Aging 2018;13:757e72.
  21. Gritz DC, Montes C, Atalla LR, et al. 
Histochemical localization of superoxide production in experimental autoimmune uveitis. Curr Eye Res 1991;10:927-931.
  22. Behndig A, Karlsson K, Johansson BO, et al. Superoxide dismutase isoenzymes in the normal and diseased human cornea. Invest Ophthalmol Vis Sci 2001;42:2293-2296.
  23. Ward SK, Wakamatsu TH, Dogru M, et al. The role of oxidative stress and inflammation in conjunctivochalasis. Invest Ophthalmol Vis Sci 2010;51:1994-2002.
  24. Wakamatsu TH, Dogru M, Ayako I, et al. Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease. Mol Vis. 2010;16:2465-2475.
  25. Ma M, Ma X, Cui J et al. Cyclosporin A Protected Cardiomyocytes Against Oxidative Stress Injury by Inhibition of NF-κB Signaling Pathway. Cardiovasc Eng Technol. 2019;10:329-343.
  26. Leonardi A, Doan S, Amrane M et a. A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis: The VEKTIS Study., Ophthalmology. 2019;126:671-681.
  27. Hingorani M, Calder VL, Buckley RJ, et al. The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest Ophthalmol Vis Sci 1999:40:392–399.